Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Merck
McKinsey
Cerilliant
UBS
Chinese Patent Office
Cantor Fitzgerald
Argus Health
Express Scripts

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,354,409

« Back to Dashboard

Which drugs does patent 8,354,409 protect, and when does it expire?

Patent 8,354,409 protects COMBIGAN and is included in one NDA.

This patent has twenty-two patent family members in nineteen countries.
Summary for Patent: 8,354,409
Title:Combination of brimonidine and timolol for topical ophthalmic use
Abstract: Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.
Inventor(s): Chang; Chin-Ming (Tustin, CA), Beck; Gary J. (Fullerton, CA), Pratt; Cynthia C. (Mission Viejo, CA), Batoosingh; Amy L. (Mission Viejo, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:13/308,507
Patent Claim Types:
see list of patent claims
Composition; Use;

Drugs Protected by US Patent 8,354,409

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan COMBIGAN brimonidine tartrate; timolol maleate SOLUTION/DROPS;OPHTHALMIC 021398-001 Oct 30, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up Y REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH ELEVATED INTRAOCULAR PRESSURE OR GLAUCOMA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,354,409

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,474,751 Combination of brimonidine and timolol for topical ophthalmic use ➤ Sign Up
7,323,463 Combination of brimonidine and timolol for topical ophthalmic use ➤ Sign Up
7,642,258 Combination of brimonidine and timolol for topical ophthalmic use ➤ Sign Up
7,030,149 Combination of brimonidine timolol for topical ophthalmic use ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Teva
US Department of Justice
Boehringer Ingelheim
Julphar
Moodys
Fuji
Covington
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.